21
Jul 2015Interview of Rafi Mardachti, Universal Biotech’s CEO
Discover the interview of Rafi Mardachti, Universal Biotech’s CEO about the 7th edition of Universal Biotech’s Innovation Prize. Read the original article here (French) The French company specializing in biotechnology consulting Universal Biotech launched the Innovation Prize in 2009. Globally recognized for the quality of the received and selected applications, this Prize is currently in the pre-selection phase for it’s 7th edition. Interview with Rafi…
21
Jul 201521
Jul 2015InnaVirVax présente les résultats très encourageants de la première étude clinique testant l’immunothérapie VAC-3S contre le VIH – France Biotech
L’association a pour but de promouvoir le développement de l’industrie des biotechnologies et des sciences de la vie en France
20
Jul 2015Sensorion réalise avec succès un placement privé international de 8 millions d’euros pour accélérer sa stratégie de développement – France Biotech
L’association a pour but de promouvoir le développement de l’industrie des biotechnologies et des sciences de la vie en France
20
Jul 201520
Jul 2015«Le Bioxparc Marrakech nécessitera 1,4 milliard d’euros» | Challenge.ma
Marrakech abritera un grand parc industriel dédié aux biotechnologies et aux sciences de la vie. Salvatore Torrente qui dirige le groupe qui porte le projet
20
Jul 2015Tour de table : Bien gérer le timing pour performer, Fusacq Buzz
Tour de table : Bien gérer le timing pour performer, Fusacq Buzz
17
Jul 2015Partnership over acquisition: Could the Juno-Celgene deal be the new norm for biotech?
When Seattle biotech Juno Therapeutics announced a history-making deal with New Jersey-based Celgene Corp. at the end of June, analysts had mixed reactions.
17
Jul 2015Immunocore completes $320 million (£205 million) private financing round
Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced the completion of a US $320 million (GBP £205 million) private financing round.
16
Jul 2015Apogenix inks cancer drug development deal for China
Germany’s Apogenix, which is backed by SAP co-founder Dietmar Hopp, has struck an exclusive licensing agreement with CANbridge Life Sciences to develop and commercialize its lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong.